COCP Earnings

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Published August 14, 2025 at 12:00 PM

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

Related Questions

What is the status of the company's cash position and runway, and does it require additional financing or dilution? How does the progress of Cocrystal's antiviral programs compare with those of peer companies (e.g., Gilead, Pfizer, Moderna) in the same therapeutic area? What regulatory risks exist for the antiviral candidates (e.g., FDA, EMA, other global agencies) and how might they impact timing or approval likelihood? Are there any partnership, licensing, or acquisition activities announced that could affect future revenue streams or risk exposure? What is the impact of the reported sentiment score (40) on market perception, and does it reflect broader investor sentiment? What are the potential catalysts (positive or negative) that could cause short‑term price volatility (e.g., data readouts, conference presentations, regulatory decisions)? How does the company's debt structure and covenants affect its ability to fund ongoing R&D? What is the historical performance of Cocrystal's stock around earnings releases and how does that inform expected price movement? Are there any non‑financial risks (e.g., legal, IP, manufacturing) mentioned that could affect the company's outlook? What is the implied breakeven point for the antiviral programs based on current cost structure and projected market size? What are the key upcoming milestones for the antiviral pipeline (e.g., IND filing, Phase II/III start, FDA submission dates) and how likely are they to be met on schedule? How do the pipeline updates affect the company's valuation multiples (e.g., EV/EBITDA, price‑to‑sales) and the current stock price? How did Cocrystal's Q2 2025 revenue and earnings compare to the same quarter last year and to analyst expectations? What are the specific financial metrics (revenue, net loss, cash burn, R&D spend) and how have they trended versus the prior quarter and the same period in 2024? What guidance does the company provide for the next 12‑18 months, and how does that compare to consensus forecasts?